Zami Aberman
2015
In 2015, Zami Aberman earned a total compensation of $1M as Co, CEO at Pluristem Therapeutics, a 2% decrease compared to previous year.
Compensation breakdown
| Salary | $484,400 |
|---|---|
| Stock Awards | $512,000 |
| Other | $18,813 |
| Total | $1,015,213 |
Aberman received $512K in stock awards, accounting for 50% of the total pay in 2015.
Aberman also received $484.4K in salary and $18.8K in other compensation.
Rankings
In 2015, Zami Aberman's compensation ranked 7,869th out of 13,638 executives tracked by ExecPay. In other words, Aberman earned more than 42.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,869 out of 13,638 | 42nd |
Division Manufacturing | 2,985 out of 5,190 | 43rd |
Major group Chemicals And Allied Products | 1,075 out of 1,854 | 42nd |
Industry group Drugs | 868 out of 1,528 | 43rd |
Industry Biological Products, Except Diagnostic Substances | 146 out of 254 | 43rd |
Source: SEC filing on April 3, 2018.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2015.
2015
Yaky Yanay
Pluristem Therapeutics
Chief Executive Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019